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Association between screening and the thyroid cancer 
“epidemic” in South Korea: evidence from a nationwide study
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ABSTRACT
OBJECTIVE
To investigate whether screening for thyroid cancer led 
to the current “epidemic” in South Korea.
DESIGN
Review of the medical records of nationally 
representative samples of patients with a diagnosis of 
thyroid cancer in 1999, 2005, and 2008.
SETTING
Sample cases were randomly selected from South 
Korea’s nationwide cancer registry, using a systematic 
sampling method after stratification by region.
PARTICIPANTS
5796 patients with thyroid cancer were included (891 
in 1999, 2355 in 2005, and 2550 in 2008).
MAIN OUTCOME MEASURES
The primary outcome was age standardised incidence 
of thyroid cancer and the changes in incidence 
between 1999 and 2008 according to the methods 
used to detect tumours (screen detection versus 
clinical detection versus unspecified).
RESULTS
Between 1999 and 2008, the incidence of thyroid 
cancer increased 6.4-fold (95% confidence interval 
4.9-fold to 8.4-fold), from 6.4 (95% confidence interval 
6.2 to 6.6) per 100 000 population to 40.7 (40.2 to 
41.2) per 100 000 population. Of the increase, 94.4% 
(34.4 per 100 000 population) were for tumours less 
than 20 mm, which were detected mainly by screening. 
97.1% of the total increase was localised and regional 
tumours according to the Surveillance, Epidemiology, 
and End Results (SEER) summary stage. Where cases 
were clinically detected, 99.9% of the increased 
incidences (6.4 per 100 000 population) over the same 
period were tumours less than 20 mm.
CONCLUSION
The current “epidemic” of thyroid cancer in South 
Korea is due to an increase in the detection of small 
tumours, most likely as a result of overdetection. 
Concerted efforts are needed at a national level to 
reduce unnecessary thyroid ultrasound examinations 
in the asymptomatic general population.
Introduction
In recent decades the incidence of thyroid cancer has 
increased steadily and consistently in many developed 
countries,1  most notably in South Korea, where the inci-
dence increased by more than sevenfold, from 6.3 per 
100 000 population in 1999 to 47.5 per 100 000 popula-
tion in 2009.2  During that time, thyroid cancer became 
the most commonly diagnosed cancer in 2004 for 
women, and in 2009 for men and women combined.2 3 
South Korea has the highest incidence of thyroid cancer 
in the world,4  which has raised public concern about 
the potential cause and also about the financial burden 
on the national healthcare system. The economic bur-
den of thyroid cancer in South Korea increased about 
sevenfold, from $257m (£207m; €232m) in 2000 to 
$1724m in 2010,5  and outcomes could be similar for 
other countries. In the United States, for example, the 
incidence of thyroid cancer is expected to surpass that 
of colorectal cancer, to become the fourth most com-
mon malignancy by 2030.6  As such, the economic bur-
den of well differentiated thyroid cancer in the United 
States is estimated to increase from more than $1.6b in 
2013 to more than $3.5b in 2030.7  Overdiagnosis is con-
sidered the most plausible explanation for this “epi-
demic” of thyroid cancer worldwide, especially in 
South Korea.8 9  Thyroid cancer related mortality has 
remained stable for several decades,1 2  despite there 
being no major improvement in treatment, as exempli-
fied by the trend in thyroid cancer incidence and mor-
tality in South Korea (fig 1 ).10  Further evidence shows a 
close correlation between the incidence rate of thyroid 
cancer and rates of screening for thyroid cancer by 
ultrasonography. In South Korea, previous studies 
reported a good correlation between the incidence of 
thyroid cancer in 2009 and screening rates in 2008 and 
2009.8 11
Some investigators have, however, questioned the 
idea that overdiagnosis is the main cause of the cur-
rent notable increase in cases of thyroid cancer.12–14  In 
a registry based cancer study,12  investigators observed 
that the incidence of both small and large thyroid 
tumours and the incidence of intrathyroidal and 
 extrathyroidal cancers12  substantially increased from 
1983 to 2006 in the United States. The researchers con-
cluded that improved detection does not fully explain 
WHAT IS ALREADY KNOWN ON THIS TOPIC
An increase in the incidence of thyroid cancer with little change in mortality has 
been observed in most countries
The increased incidence of thyroid cancer is mainly due to detection of small, well 
differentiated thyroid tumours
Overdiagnosis is considered to be the most plausible explanation; however, some 
remain unconvinced and have questioned this idea
WHAT THIS STUDY ADDS
This nationwide study found that the increase in thyroid cancer cases was due to an 
increase in the incidence of small tumours, which were detected mainly through 
screening
Screening for thyroid cancer can detect small tumours, as well as clinically indolent 
asymptomatic tumours with local extension and lymph node involvement
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the rising incidence of thyroid cancer.12  In Australia, 
an increase in thyroid cancer at early and advanced 
stages was observed across a range of sociodemo-
graphic groups.13  Furthermore, there were no substan-
tial differences in tumour size, invasion, lymph node 
involvement, or distant metastasis between inciden-
tally and non-incidentally diagnosed thyroid cancers 
in the United States.14 In this nationwide epidemiolog-
ical study we investigated the recent increase in cases 
of thyroid cancer in relation to the methods used to 
detect tumours. 
Methods
To investigate the reasons for the rapid increase in inci-
dence of thyroid cancer in South Korea, in 2010 the 
Korea Central Cancer Registry conducted National Epi-
demiologic Survey of Thyroid cancer (NEST), which was 
designed to collect a representative sample of people 
with a diagnosis of thyroid cancer in 1999, 2005, or 
2008. The study methods have been described previ-
ously,15 and the dataset is available on request (http://
kccrsurvey.cancer.go.kr/index.do).
We selected the study population from the registry 
database of all registered patients with thyroid cancer 
(3342 in 1999, 12 659 in 2005, and 26 890 in 2008). To do 
this, we used a two stage sampling method. Firstly, we 
used a probability-proportional-to-size method that 
was stratified by region in a given year to select 24 hos-
pitals. Then we used a systematic sampling method to 
randomly select cases within each hospital. The num-
ber of cases diagnosed in 1999 and 2005 was smaller 
than in 2008, thus we applied different sampling pro-
portions for each study year (33% in 1999, 22% in 2005, 
and 11% in 2008).
Using a predesigned data collection form, we col-
lected basic personal variables from medical records. 
These included age and sex, and tumour related vari-
ables, such as tumour size, histological type, status of 
nodal and distant metastases, tumour stage (American 
Joint Committee on Cancer, cancer staging manual, 
sixth edition,16  Surveillance, Epidemiology, and End 
Results (SEER) summary staging manual17 ), and the 
way in which the tumour was detected. The SEER 
 summary stage grouped thyroid cancers into three 
major categories—localised, regional, and distant. 
The regional stage includes regional by direct extension 
only, only regional lymph nodes involved, and regional 
by both direct extension and regional lymph node 
involvement.17
In our study, we further categorised the regional 
stage into five subgroups according to lymph node 
involvement (yes or no) and the degree of extrathyroi-
dal extension (none, minimal, or gross).16 18 The way in 
which a tumour was detected was classified as screen 
detected (through cancer screening as recorded in med-
ical records), clinically detected (by investigation of 
symptoms associated with thyroid disease, including 
thyroid cancer), and unspecified (or unknown). The his-
tological subtypes of thyroid cancer were classified 
according to the International Classification of Diseases 
for Oncology, third edition19  as papillary carcinoma, 
medullary carcinoma, follicular carcinoma, anaplastic 
carcinoma, and others.20
Of 6846 patients selected at the first stage (1103 in 
1999, 2785 in 2005, and 2958 in 2008), we excluded 1050 
cases from the final analysis. These included 960 cases 
where the hospital refused to disclose medical records, 
and 90 cases with insufficient data in the medical 
records. Overall, 5796 patients were included in this 
study (891 in 1999, 2355 in 2005, and 2550 in 2008). To 
check whether the database of the National Epidemio-
logic Survey of Thyroid Cancer was comparable with the 
National Cancer Incidence Database, we compared the 
age and sex distribution (see supplementary table 1) 
and the estimated age standardised incidence of thy-
roid cancer (see supplementary table 2). The results 
from the two surveys were comparable for each 
given year. 
Statistical analysis
We estimated the age standardised incidence rate of 
thyroid cancer for the three methods of tumours detec-
tion (screen versus clinical versus unspecified) by 
tumour size and SEER summary stage, for 1999, 2005, 
and 2008. To estimate the age standardised incidence of 
thyroid cancer, we calculated a weighted frequency for 
each five year age group for each study year, and then 
divided the weighted frequency by the corresponding 
mid-year population. The age standardised incidence 
rate was estimated using the weights for the propor-
tions of corresponding five year age groups in the world 
standard (using Segi’s standard population).21 The 95% 
confidence interval was calculated per 100 000 popula-
tion (assuming that a Poisson distribution is appropri-
ate). We calculated the absolute differences in the 
incidence of thyroid cancer according to the method of 
tumour detection by tumour size, SEER summary stage, 
and the American Joint Committee on Cancer stage 
between 1999 and 2008.
The baseline characteristics are presented as means 
with standard deviations or numbers (percentages), by 
year of detection. We used one way analysis of variance 
to compare the differences in continuous variables by 
year and a χ2test to compare the differences in categori-
cal variables by year. P values of less than 0.05 were 


























































































Fig 1 | Trends in incidence of and mortality from thyroid 
cancer in South Korea, 1999–2012. The age standardised 
rates use Segi’s world standard population
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 analyses were performed using Stata 12.0 (StataCorp LP, 
TX) and SAS 9.3 (SAS Institute, Cary, NC).
Patient involvement
This study is a retrospective medical chart review of 
patients selected from the national cancer registry data-
base. There was no direct contact with patients or indi-
viduals. No patients were involved in setting the 
research questions or the outcome measures, nor were 
they involved in developing plans for recruitment, 
design, or implementation of the study. No patients 
were asked to advise on interpretation or writing up of 
results. The dataset for this study is available from 
http://kccrsurvey.cancer.go.kr/index.do on request.
Results
Table 1 shows the characteristics of the study popula-
tion for each study year. Overall, 84.5% of the partici-
pants (n=5796) were women, and the mean (SD) age 
was 46.9 (12.4) years. The most common histological 
type (94.9%) was papillary carcinoma. The size of thy-
roid tumours steadily decreased from 1999 to 2008. The 
proportion of screen detected tumours increased from 
15.0% in 1999 to 56.1% in 2008. The proportion of 
regional stage thyroid cancer increased from 47.7% in 
1999 to 59.1% in 2008, while the proportion of localised 
SEER summary stage thyroid cancer remained station-
ary. The proportion of distant stage thyroid cancer 
decreased from 5.4% in 1999 to 1.3% in 2008.
Change in incidence of thyroid cancer over time by 
tumour size
Table 2  and figure 2 (top panel) show the changes in the 
estimated incidence of thyroid cancer by tumour size 
for each method of tumour detection during 1999-2008. 
The incidence of screen detected tumours less than 10 
mm increased steeply, from 0.27 (95% confidence inter-
val 0.22 to 0.31) per 100 000 population in 1999 to 15.00 
(14.70 to 15.29) per 100 000 population in 2008, with an 
absolute difference of 14.73. The incidence of clinically 
detected tumours less than 10 mm also showed a mod-
est increase, from 0.49 per 100 000 population in 1999 
to 4.88 per 100 000 population in 2008 (absolute differ-
ence 4.39). There was only a fractional increase in the 
incidence of screen detected tumours 30 mm or more 
and no significant increase in the incidence of such 
tumours detected clinically (absolute difference 0.00, 
95% confidence interval −0.27 to 0.27). Overall, 94.4% 
of the total increase was attributed to the higher inci-
dence of tumours less than 20 mm. The increase in inci-
dence of such tumours accounted for 99.9% of the 
increase in clinically detected thyroid cancer, compared 
with 93.7% of the increase in screen detected tumours.
About 60% of the absolute increase in thyroid cancer 
incidence between 1999 and 2008 occurred during 
2005-08, especially for screen detected cases, where 
tumours were less than 20 mm.
Changes in incidence of thyroid cancer over time by 
SEER summary stage
Table 2  and figure 2 (bottom panel) show the changes in 
estimated incidence of thyroid cancer according to the 
SEER summary stage. Overall, between 1999 and 2008 
there was a 6.7-fold (95% confidence interval 5.8-fold to 
7.8-fold) increase in localised stage tumours and an 
8.1-fold (7.2-fold to 9.2-fold) increase in regional stage 
tumours. This increase in regional stage tumours 
accounted for 61.6% of the total increase in thyroid can-
cer incidence between 1999 and 2008, and 35.5% of the 
total increase was due to the increase in localised stage 




P value*1999 2005 2008
Overall 5796 891 2355 2550
Mean (SD) age (years) 46.9 (12.4) 46.0 (14.3) 47.3 (12.5) 46.8 (11.6) 0.03
Mean (SD) tumour size (mm) 13.3 (11.7) 21.5 (15.9) 13.6 (11.1) 10.5 (9.0) <0.01
Sex: 0.01
 Men 898 (15.5) 136 (15.3) 328 (13.9) 434 (17.0)
 Women 4898 (84.5) 755 (84.7) 2027 (86.1) 2116 (83.0)
Methods of detection†: <0.01
 Screening 2655 (45.8) 134 (15.0) 1090 (46.3) 1431 (56.1)
 Clinical 1784 (30.8) 447 (50.2) 773 (32.8) 564 (22.1)
 Unspecified 1357 (23.4) 310 (34.8) 492 (20.9) 555 (21.8)
Histological type‡: <0.01
 Follicular carcinoma 173 (3.0) 62 (7.0) 66 (2.8) 45 (1.8)
 Papillary carcinoma 5500 (94.9) 779 (87.4) 2243 (95.2) 2478 (97.2)
 Medullary carcinoma 43 (0.7) 13 (1.4) 19 (0.8) 11 (0.4)
 Anaplastic carcinoma 26 (0.5) 15 (1.7) 6 (0.3) 5 (0.2)
 Other 54 (0.9) 22 (2.5) 21 (0.9) 11 (0.4)
Regional lymph node involvement: <0.01
 No 2466 (42.6) 268 (30.1) 1012 (43.0) 1186 (46.5)
 Yes 2047 (35.3) 319 (35.8) 799 (33.9) 929 (36.4)
 Unknown 1283 (22.1) 304 (34.1) 544 (23.1) 435 (17.1)
Distant metastasis: <0.01
 No 5380 (92.8) 774 (86.9) 2196 (93.3) 2410 (94.5)
 Yes 34 (0.6) 15 (1.7) 14 (0.6) 5 (0.2)
 Unknown 382 (6.6) 102 (11.4) 145 (6.1) 135 (5.3)
Extrathyroidal extension: <0.01
 No 2783 (48.0) 397 (44.5) 1194 (50.7) 1192 (46.7)
 Yes 2593 (44.7) 357 (40.1) 993 (42.2) 1243 (48.8)
 Unknown 420 (7.3) 137 (15.4) 168 (7.1) 115 (4.5)
Focality: <0.01
 Unifocal 3810 (66.7) 554 (62.2) 1553 (65.9) 1703 (66.8)
 Multifocal 1697 (29.3) 234 (26.3) 689 (29.3) 774 (30.3)
 Unknown 289 (5.0) 103 (11.5) 113 (4.8) 73 (2.9)
American Joint Committee on 
Cancer stage:
<0.01
 I 3038 (52.4) 428 (48.0) 1249 (53.0) 1361 (53.3)
 II 49 (0.9) 14 (1.6) 23 (1.0) 12 (0.5)
 III 1036 (17.9) 97 (10.9) 373 (15.8) 566 (22.2)
 IV 426 (7.3) 101 (11.3) 178 (7.6) 147 (5.8)
 Unknown 1247 (21.5) 251 (28.2) 532 (22.6) 464 (18.2)
SEER summary stage: <0.01
 Localised 2125 (36.6) 302 (33.9) 919 (39.0) 904 (35.5)
 Regional 3176 (54.8) 425 (47.7) 1243 (52.8) 1508 (59.1)
 Distant 126 (2.2) 48 (5.4) 45 (1.9) 33 (1.3)
 Unknown 369 (6.4) 116 (13.0) 148 (6.3) 105 (4.1)
SEER=Surveillance, Epidemiology, and End Results.
*Calculated by one way analysis of variance for continuous variables and χ2test for categorical variables.
†Classified as screen detected (as recorded in medical records), clinically detected (through investigation of 
symptoms associated with thyroid disease, including thyroid cancer), and unspecified (or unknown).
‡Classified based on International Agency for Research on Cancer (international classification of diseases for 
oncology, third edition). Extrathyroidal extension was determined on the basis of the American Joint Committee 
on Cancer (cancer staging manual, sixth edition).
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tumours. The incidence of distant stage thyroid cancer, 
however, increased little between 1999 and 2008.
A large increase was observed in the incidence of 
screen detected localised and regional stage cancers. 
The incidence of screen detected localised stage cancer 
increased by 8.4-fold from 1999 to 2008, and clinically 
detected localised stage thyroid cancer increased by 
2.6-fold during the same period. The incidence of screen 
detected regional stage cancer increased by 38.2-fold, 
from 0.37 per 100 000 population in 1999 to 14.15 per 
100 000 population in 2008. The incidence of clinically 
detected regional stage cancer increased by 3.5-fold 
from 1999 to 2008. In contrast, there was only a frac-
tional increase in the incidence of screen detected dis-
tant stage thyroid cancer, and there was no significant 
change in the incidence of clinically detected distant 
stage thyroid cancer (absolute difference −0.02, 95% 
confidence interval −0.14 to 0.10).
Subgroup analysis of regional SEER summary stage 
tumours
The regional SEER summary stage includes tumours 
with regional lymph node involvement and those with 
extrathyroidal extension. To better understand the true 
nature of the increase in the incidence of regional stage 
tumours over time, we further analysed the regional 
stage thyroid tumours by lymph node involvement (yes 
or no) and the degree of extrathyroidal extension (none, 
minimal, gross) according to the detection method by 
year (table 3  and fig 3). Most of the increase in incidence 
of regional stage thyroid cancer was due to lymph node 
involvement, about two thirds of which were with min-
imal extrathyroidal extension and one third without 
extrathyroidal extension. For the tumours without 
lymph node involvement, minimal extrathyroidal 
extension accounted for virtually all of the increase 
between 1999 and 2008. In terms of tumour detection 
method, there was a greater increase in the incidence of 
screen detected regional stage thyroid cancer than clin-
ically detected regional stage tumours (absolute 
 difference 13.8 v 3.9), even for the tumours with lymph 
node involvement (absolute difference 8.3 v 2.2).
Changes in tumour size over time by method of 
tumour detection
Overall, the median size of thyroid tumours decreased 
from 18 mm in 1999 to 8 mm in 2008 (see supplementary 
figure 1 and table 3). The size of screen detected tumours 
was notably smaller than that of clinically detected 
tumours (P<0.01); however, the magnitude of the 
decrease in median tumour size over time was greater 
for the clinically detected tumours (20 mm to 9 mm) 
than for the screen detected tumours (14.5 mm to 8 mm).
Regional lymph node involvement by tumour size 
and method of tumour detection
Supplementary table 4 shows the status of regional 
lymph node involvement by tumour size according to the 
methods of tumour detection. Overall, even tumours less 
than 10 mm were found to have regional lymph node 
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1999 and 28.4% in 2008. As the tumour size increased to 
10–20 mm, 20–30 mm, and 30 mm or more, the propor-
tion of cases with positive regional lymph node involve-
ment increased accordingly. However, the method of 
tumour detection did not have any real impact on the 
status of regional lymph node involvement.
Discussion
Our study shows that most of the recent increases in the 
incidence of thyroid cancer in South Korea was due to 
greater detection of small (<20 mm) tumours, which 
accounted for 94.4% of the overall increase (34.4 per 
100 000 population) in the estimated incidence of thy-
roid cancer between 1999 and 2008. This increase is 
likely to be associated with the widespread practice of 
screening for thyroid cancer using ultrasonography, 
which started in the early 2000s in South Korea.8 22  In 
our study, 97.1% of the increase in estimated incidence 
of thyroid cancer was due to greater detection of 
regional and localised stage tumours, for which five 
year relative rates of survival were 100.1% and 100.4%, 
respectively, in South Korea.23 This finding of more than 
100% relative survival rates means that people who 
have thyroid cancer and who are more likely to be 
screened for the cancer might be healthier and have a 
lower risk of dying than the general population, even in 


































































































































































Screen detection Clinical detection Overall
Fig 2 | Differences in age standardised incidence of thyroid cancer per 100 000 population 
during 1999–2008 and 2005–2008 by tumour size (top panel) and by Surveillance, 
Epidemiology, and End Results (SEER) summary stage (bottom panel). Error bars represent 
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those with regional stage thyroid cancer by Surveil-
lance, Epidemiology, and End Results (SEER) summary 
stage.
The increase in the estimated incidence of screen 
detected tumours only accounted for 66.1% of the total 
increase in incidence of thyroid cancer between 1999 
and 2008, and clinically detected tumours accounted 
for an additional 18.7% of the increase. Some might 
argue that this finding is inconsistent with the idea of 
overdetection as a major contributor to the recent thy-
roid cancer “epidemic.” However, we believe the oppo-
site to be true. Overdetection of clinically indolent 
thyroid cancers is the best explanation for the observed 
findings in our study.
In fact, routine ultrasound examination and biopsy 
of any thyroid nodule less than 10 mm is not recom-
mended in the absence of high risk clinical features.24 
Interestingly, the median size for clinically detected 
tumours was only 9 mm in 2008 (it was 20 mm in 1999), 
which was similar to the median size of 8 mm for screen 
detected tumours in 2008 (see supplementary figure 1). 
Practically, tumours of 8-9 mm are just too small for 
patients to notice or doctors to find at such high rates. 
To be palpable or to cause symptoms at such a size the 
tumours would all have to be located at the isthmus or 
external surface of the thyroid, or be invading or press-
ing on the trachea, recurrent laryngeal nerve, or 
oesophagus, which is extremely unlikely. This raises 
serious questions about the true nature of clinically 
detected thyroid cancer, because it is not possible that 
so many tumours of less than 20 mm were detected 
 clinically.
Furthermore, about 60% of the total increase in thy-
roid cancer incidence between 1999 and 2008 occurred 
over just three years (2005-08), and the rising trend 
continued even after that period (fig 1) . However, in 
2014 a public awareness campaign was launched 
against routine screening for thyroid cancer, and within 
one year there was a 35% decrease in the number of 
 thyroid cancer surgeries undertaken.25  Taken together 
with the accumulating data—which showed that mor-
tality from thyroid cancer had remained stable for 
decades, despite the rapid increase in its incidence 
(fig 1 )8 26—our findings provide further evidence for 
overdetection as a major contributor to the current 
 thyroid cancer “epidemic” in South Korea.
Strengths and weaknesses of this study
Our study is meaningful as a nationwide survey that 
shows the change in incidence of thyroid cancer over 
time using a representative random sample of patients 
from cancer registry data. In addition, the study enables 
a better understanding of the mechanisms by which the 
incidences of thyroid cancer have recently increased, by 
analysing the data according to the methods of tumour 
detection and detailed pathological findings, including 
the size of tumour and nodal status.
However, this study has some limitations. Our data 
might have a misclassification bias for methods of 
tumour detection, which could cause either underesti-
mation or overestimation of the incidence rate in spe-
cific subgroups. However, in our study, we used sample 
weights to calculate an unbiased estimate after adjust-
ing for the non-response units. Indeed, the estimated 
incidence from NEST data was similar to the real inci-
dence from cancer registry data (see supplementary 
tables 1 and 2). In addition, the estimated proportion of 
clinically detected cases from our findings in 2008 was 
similar to those from the Korea National Cancer Screen-
ing Survey study in 2009.27 Nevertheless, because of the 
relatively short follow-up, we could not secure the long 
term survival outcome data, which is the inherent lim-
itation of this study of thyroid cancer.
Comparison with other studies
The reason for the increasing incidence of thyroid can-
cer in the past decade has been well debated and sum-
marised in recent reviews.28 29  Many experts suggested 
that the increase was a result of imaging tools being 
used more often for screening8 9 11 26 30 ; others called for 
more epidemiological studies searching for yet uniden-
tified causal factors.12–14
Some studies have shown that the incidences of 
small and large advanced stage thyroid cancer have 
increased.12 31  Furthermore, a study of data from ter-
tiary referral hospitals in the United States reported 
that the proportion of incidentally detected thyroid 
tumours not associated with symptoms did not 
increase, despite the increasing number of thyroid can-
cer cases overall.32  One study found that tumour size, 
invasion, lymph node involvement, and distant metas-
tasis in patients with thyroid cancer detected inciden-
tally were no different from those in patients with 
non-incidentally detected cancer.14  These findings, 
however, could be explained by the indolent nature of 
well differentiated thyroid tumours, which can grow to 
be large and can go undetected (even with lymph node 
involvement, as shown in this study, and extrathyroi-
dal extension) until it is discovered incidentally 
through imaging investigations.33

































































































Fig 3 | Absolute change over time in incidence of regional stage thyroid cancer by lymph 
node involvement and degree of extrathyroidal extension according to detection methods. 
Error bars represent 95% confidence intervals of differences in age standardised incidence 
during study period
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To date, the only confirmed risk factor for thyroid 
cancer is exposure to ionising radiation.34  In South 
Korea, however, there were no discernible sources of 
additional radiation exposure other than the medical 
use of radioisotopes and diagnostic procedures, such as 
computed tomography.11 27 35 Even if there were some 
increases in the incidence of thyroid cancer as a result 
of all those environmental factors, their contribution 
would be small. If the steep increase in incidence of thy-
roid cancer in South Korea is not a result of overdetec-
tion, it is hard to find a reasonable explanation for our 
findings of a 20.1-fold increase in small tumours (<10 
mm) and an 8.1-fold increase in regional stage tumours 
over the period 1999 to 2008.
Overdetection starts at the macro level, with how 
healthcare service is paid for at the system level, and 
extends down to the micro level, with how pathological 
specimens are processed now compared with how they 
were examined 30 years ago.28 29  The increase in thyroid 
cancer incidence in South Korea coincides with the 
widespread use of ultrasound examination in local clin-
ics, which followed reform of the nation’s healthcare 
system in 2000. Many hospitals and clinicians encour-
aged routine health checks, which included the option 
of screening for thyroid cancer (for an additional fee, as 
this was not covered by national health insurance). A 
study of 10 major hospitals showed that the annual 
number of ultrasound examinations of the thyroid 
almost doubled between 2001 and 2004, and the 
annual number of examinations using ultrasound 
guided fine needle aspiration almost quadrupled 
during the same period.22  At the microscopic level, 
more careful examination of resected thyroid speci-
mens could well have contributed to the increase in 
incidence of thyroid cancer.36
Generally, only nodules of more than 1 cm are recom-
mended for further evaluation.24  If there is no increase 
in size or evidence of clinical progression of the 
tumour, some investigators recommend clinical obser-
vation for small papillary thyroid cancers, because 
they do not usually develop so aggressively.37–40  In 
South Korea, there was no discrete guideline for fur-
ther evaluation of thyroid nodules until 2010, when the 
Korean Endocrine Society published a new guideline 
recommending the use of fine needle aspiration cytol-
ogy for thyroid nodules of more than 5 mm.41  However, 
because small papillary tumours are usually less 
aggressive there has been growing concern about the 
potential harm from side effects of unnecessary evalu-
ation and subsequent treatment. Recently, a multidis-
ciplinary expert committee, organised by the National 
Cancer Center Korea, developed a guideline for thyroid 
cancer screening. A consensus was that thyroid ultra-
sonography is not routinely recommended for healthy 
people.42
Conclusion and policy implications
Our study shows that the increase in the incidence of 
thyroid cancer in South Korea mainly resulted from 
overdetection, most likely as a result of widespread 
use  of sensitive imaging tools (eg, ultrasound 
 examination). Considering the increase in thyroid can-
cer  incidence,1 2  the financial burden of using ultra-
sound to detect small tumours (and the often 
unnecessary subsequent surgery) is expected to rise 
rapidly.5–7 Concerted efforts are needed at national level 
to reduce unnecessary ultrasound examination of the 
thyroid in the asymptomatic general population, unless 
clinically indicated.
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